International Stem
Cell is focused on exploring and advancing the therapeutic applications of
human stem cells as well as the development and commercialization of cell-based
biomedical products. The company was the first to develop and perfect a new
class of human stem cells, parthenogenetic stem cells, created from
unfertilized human eggs, and has established a strong patent portfolio offering
clean intellectual property and freedom to operate.
Utilizing a strategy
much different than the majority of other players in the biotech space,
International Stem Cell generates revenues from its individual subsidiary
business units that sell products developed from scientific discoveries made by
International Stem Cell. Not only is this model self-sustaining with revenues
used to support scientific research and development, it also provides
practical, short-term applications of the core technologies.
The Lifeline Cell
Technology (LCT) and Lifeline Skin Care (LSC) commercial businesses provide the
foundation for International Stem Cell’s short-term application. For the
six-months ended June 30, 2013, International Stem Cell reported revenues of
$2.74 million, compared to revenues of $2.13 million for the prior year period.
LCT contributed $1.38 million, up 30 percent year-over-year, while LSC
contributed $1.36 million, an increase of 27 percent from the same period in
2012.
Therapeutic
programs, including those addressing Parkinson’s disease, metabolic liver
disease and corneal blindness, make up International Stem Cell’s medium-term
applications. In regards to its Parkinson’s disease program, International Stem
Cell has carried out several stem cell-based experiments and recently concluded
its first pilot primate study with favorable results. In mid-2104, the company
plans to submit to the U.S. FDA an investigational new drug (IND) application,
and recently engaged Duke University as a partner to carry out the phase I
clinical study of Parkinson’s disease in human subjects.
International Stem
Cell’s long-term strategy is focused on therapeutic products, licensing revenue
and the company’s stem cell bank, UniStemCell, the life science industry’s
first collection of non-embryonic histocompatible human stem cells available
for research and commercial use.
Each aspect of
International Stem Cell’s business model is centered on the company’s
proprietary stem cell technology. The company’s stem cells present superior
immune matching capabilities and can be used in millions of people, regardless
of their sex or racial background, with minimized expectation of immune
rejection following transplantation.
For more information
visit www.internationalstemcellcorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment